Regeneron (REGN) Tops Q3 EPS by 69c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Reports Third Quarter 2018 Financial and Operating Results
November 6, 2018 6:30 AM ESTTARRYTOWN, N.Y., Nov. 6, 2018 /PRNewswire/ --Â
Third quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 7% to $1.02 billion versus third quarter 2017, and third quarter 2018 EYLEA global net sales(1) increased 11% to $1.68 billion versus third quarter 2017 U.S. launch of Libtayo® (cemiplimab-rwlc) Injection for the treatment of patients with cutaneous squamous cell carcinoma (CSCC) underway U.S. launch of Dupixent® (dupilumab) Injection in patients with moderate-to-severe asthma underway FDA approval of EYLEA for an every 12-week dosing regimen in patients with wet age-related macular degeneration (wet AMD)... More